Abstract:Abstract Background Multiple breast cancer gene expression profiles have been developed that appear to provide similar abilities to predict outcome and may outperform clinical-pathologic criteria; however, the extent to which seemingly disparate profiles provide additive prognostic information is not known, nor do we know whether prognostic profiles perform equally across clinically defined breast cancer subtypes. We evaluated whether combining the prognostic powers of standard breast cancer clinical variables with a large set of gene expression signatures could improve on our ability to predict patient outcomes. Methods Using clinical-pathological variables and a collection of 323 gene expression "modules", including 115 previously published signatures, we build multivariate Cox proportional hazards models using a dataset of 550 node-negative systemically untreated breast cancer patients. Models predictive of pathological complete response (pCR) to neoadjuvant chemotherapy were also built using this approach. Results We identified statistically significant prognostic models for relapse-free survival (RFS) at 7 years for the entire population, and for the subgroups of patients with ER-positive, or Luminal tumors. Furthermore, we found that combined models that included both clinical and genomic parameters improved prognostication compared with models with either clinical or genomic variables alone. Finally, we were able to build statistically significant combined models for pathological complete response (pCR) predictions for the entire population. Conclusions Integration of gene expression signatures and clinical-pathological factors is an improved method over either variable type alone. Highly prognostic models could be created when using all patients, and for the subset of patients with lymph node-negative and ER-positive breast cancers. Other variables beyond gene expression and clinical-pathological variables, like gene mutation status or DNA copy number changes, will be needed to build robust prognostic models for ER-negative breast cancer patients. This combined clinical and genomics model approach can also be used to build predictors of therapy responsiveness, and could ultimately be applied to other tumor types.

Novel Model for Comprehensive Assessment of Robust Prognostic Gene Signature in Ovarian Cancer Across Different Independent Datasets

An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

Novel Gene Signatures for Prognosis Prediction in Ovarian Cancer.

Identification and validation of a novel prognosis prediction model in adrenocortical carcinoma by integrative bioinformatics analysis and statistics and machine learning

Identification of a G-protein coupled receptor-related gene signature through bioinformatics analysis to construct a risk model for ovarian cancer prognosis

Construction and Validation of a Novel Glycometabolism-Related Gene Signature Predicting Survival in Patients With Ovarian Cancer

Identification of Subpathway Signatures For Ovarian Cancer Prognosis by Integrated Analyses of High-Throughput miRNA and mRNA Expression.

Comprehensive assessment gene signatures for clear cell renal cell carcinoma prognosis

A Novel 4-Gene Signature Model Simultaneously Predicting Malignant Risk of Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma Prognosis.

Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts

Protein expression profiling identifies a prognostic model for ovarian cancer

A risk model of gene signatures for predicting platinum response and survival in ovarian cancer

Construction of a Prognostic Model for Ovarian Cancer Based on a Comprehensive Bioinformatics Analysis of Cuproptosis-Associated Long Non-Coding RNA Signatures

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures

A Prognostic Signature Model for Unveiling Tumor Progression in Lung Adenocarcinoma

Identification and Validation of a Gene-Based Signature Reveals SLC25A10 As a Novel Prognostic Indicator for Patients with Ovarian Cancer

Identifying Prognostic Signature in Ovarian Cancer Using DirGenerank

Identification and Validation of a Novel Prognosis Prediction Model in Adrenocortical Carcinoma by Integrative Bioinformatics Analysis, Statistics, and Machine Learning

Identification of potential biomarkers in ovarian carcinoma and an evaluation of their prognostic value

Combination of Immune-Related Genomic Alterations Reveals Immune Characterization and Prediction of Different Prognostic Risks in Ovarian Cancer